RBC Capital notes that one of Edgewise Therapeutics’ abstracts for their HCM drug EDG-7500 was leaked ahead of the presentations on September 28 and 29 at the HFSA Annual Scientific Meeting, and while the firm cannot confirm its authenticity, it “appears to be legitimate.” The purported abstract release supports the potential for EDG-7500’s profile to be superior to that of CMIs, and while the amount of data in the abstract was limited, it “does take the worst case scenario off the table,” according to the analyst, who continues to believe that ‘7500 can show impressive efficacy and would be buyers into the full data. RBC has an Outperform rating and $32 price target on Edgewise shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Unveils 2024 Equity Incentive Plan
- Truist biotech analyst holds an analyst/industry conference call
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (34c)
- 3 Best Stocks to Buy Now, 7/29/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 7/26/2024, According to Top Analysts